PROCEPT BioRobotics

PRCT: Share Price Will Likely React Sharply To Upcoming Earnings Data

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

21 Mar 25

Updated

11 Dec 25

Views

229

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-60.5%

7D

-11.2%

Loading

1Y

-60.5%

7D

-11.2%

You can edit this narrative until Dec 12 9:10 PM. Then, changes will post as Updates.

Author's Valuation

US$49.935.8% undervalued

AnalystConsensusTarget Fair Value

Shared on 11 Dec 25

Fair value Decreased 4.22%

PRCT: Stock Reaction Will Recover As Conservative Guidance And Pullback Normalize

Analysts have modestly reduced their price target on PROCEPT BioRobotics from about $52 to roughly $50 per share, reflecting slightly lower profit margin expectations even as they argue the recent share price reaction to conservative guidance and sector-wide volatility appears overdone. Analyst Commentary Bullish analysts emphasize that the recalibrated $50 price target still implies meaningful upside from current levels, as they view the recent pullback as disconnected from the company’s underlying growth trajectory and operational execution.

Shared on 27 Nov 25

Fair value Decreased 6.29%

PRCT: Stock Reaction Will Recover As Guidance Proves Conservative

Analysts have lowered their price target for PROCEPT BioRobotics from $55.60 to $52.10 per share, citing a mix of cautious company guidance and continued anticipation of healthy revenue growth, even with recent market volatility. Analyst Commentary Recent analyst reports reflect a mix of optimistic outlooks and measured caution for PROCEPT BioRobotics, as price targets have been adjusted downward in the context of ongoing market volatility and evolving company guidance.

Shared on 13 Nov 25

Fair value Decreased 8.70%

PRCT: Stock Reaction Will Normalize As Sector Volatility Subsides

The analyst consensus fair value target for PROCEPT BioRobotics has been reduced by approximately $5 to $55.60. Analysts attribute the adjustment to updated sales guidance and expectations of continued volatility in the medtech sector.

Shared on 30 Oct 25

Fair value Decreased 2.87%

Analysts have lowered their price target for PROCEPT BioRobotics from $62.70 to $60.90, citing broad MedTech market volatility and anticipated stock fluctuations. This comes despite expectations of healthy Q3 financial performance.

Shared on 16 Oct 25

Fair value Decreased 4.42%

Analysts have updated their price target for PROCEPT BioRobotics, lowering it from $64 to $50 per share. They cite expectations for healthy revenue, but also note increased market volatility and cautious investor sentiment in the MedTech sector.

Shared on 08 Aug 25

Fair value Decreased 4.41%

The modest reduction in PROCEPT BioRobotics’ consensus price target to $65.75 reflects a slight downward revision in the company’s future P/E multiple, while profitability remains stable. What's in the News Raised full-year 2025 revenue guidance to $325.5 million, representing 45% year-over-year growth; projected net loss for 2025 is $83.5 million.

Shared on 01 May 25

Fair value Decreased 31%

Shared on 24 Apr 25

Fair value Decreased 0.53%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 3.18%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 9.95%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Increased 23%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

US$49.9

35.8% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

20.24%

Medical Equipment revenue growth rate

7.21%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.78%

Calculation

US$76.74m

Earnings '28

x

48.01x

PE Ratio '28

=

US$3.68b

Market Cap '28

US$3.68b

Market Cap '28

/

59.18m

No. shares '28

=

US$62.26

Share Price '28

US$62.26 Share Price '28

Discounted to 2025 @ 7.76% p.a.

=

US$49.75

Fair Value '25